Announcement is on the ASX market sensitive .... i bought in yesterday at .33 cents...
Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 TrialEfti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung cancer is well tolerated and continues to show promising initial signals of efficacyTriple combination therapy has achieved a 67% response rate and 91% disease control rate in metastatic 1st line non-small cell lung cancer patients (N=21) despite 81% of patients having low or negative PD-L1 expression
Announcement is on the ASX market sensitive .... i bought in...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
0.015(3.57%) |
Mkt cap ! $517.1M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 44.5¢ | 42.0¢ | $1.348M | 3.109M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10725 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 14524 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
43.5¢ |
Change
0.015 ( 3.57 %) |
||||
| Open | High | Low | Volume | ||
| 42.5¢ | 44.0¢ | 42.5¢ | 697373 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| IMM (ASX) Chart |